Biocon included in S&P Global Sustainability Yearbook 2024

Sustainability is integral to Biocon's business purpose

Ashland launches iSolve information on demand for F&B customers

iSolveSM information on demand is the result of our focus on customer relationship

Sun Pharma included in S&P Global Sustainability Yearbook 2024

This recognition attests to Sun Pharma’s commitment to incorporate Environmental, Social, and Governance (ESG) principles through focused initiatives across its businesses

Lord's Mark Industries files patent for bio-chemistry reagents; Targets revenue of Rs. 200 Cr

These re-agent and diagnostic test kits come with 99.7% accuracy

Biocon Biologics partners with Sandoz Australia for Biosimilars Trastuzumab and Bevacizumab

The agreement is effective from January 1, 2024 and commercialisation commenced on February 1, 2024

Industry’s reaction to Union Budget 2024-25

Indian Pharma Post brings together the views of industry leaders on the Interim Union Budget 2024-25 announcement and its impact on the industry

Sun Pharmaceutical Industries Q3 FY24 consolidated PAT up at Rs. 2,560.54 Cr

Sun Pharmaceutical Industries has reported total income of Rs. 12,630.9 crores during the period ended December 31, 2023

Pharmatech Associates adds Dr. Praveen Tyle to Board of Trustees

Cell and gene therapy will be top industry trend for pharma in 2024, finds GlobalData

The survey data presented in “The State of the Biopharmaceutical Industry 2024” report reveals that N=21 (18%) of industry professionals were convinced that CGT will dominate as the most important trend in pharma next year

Natco Pharma and Breckenridge dismissed from antitrust lawsuit